{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Relapse/Progression defined as:\n\nNodes, liver, and/or spleen ≥50% increased or new by physical exam / imaging studies.\n\nCirculating lymphocytes ≥50% increased by morphology and/or flow cytometry. Richter's transformation by lymph node biopsy .","groups":[{"description":"Allogeneic Bone Marrow Transplantation: Undergo donor HCT\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant\n\nAutologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT\n\nCarmustine: Given IV\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV\n\nEtoposide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative study\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo donor HCT\n\nTacrolimus: Given IV or PO\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Autologous HCT, Donor HCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"1 year post-autograft","title":"Number of Patients With Relapsed/Progressive Disease","type":"SECONDARY","unitOfMeasure":"Participants"}